Wenxin (Vincent) Xu

And that is wrap for #KCRS2025 @HHammersMD @advocatekidneys @kidneycan

#KCRS25 Session 5 focused on current best practices and what's ahead in kidney cancer treatment and research. Front-Line Treatment Approaches with David McDermott Subsequent-Line Options with @motzermd Adjuvant Therapy Options with @NaomiHaas5 Treatment of Rare Subtypes with…

KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC #KCRS25 #RCC @VincentWenxinXu @DanaFarberNews onclive.com/view/kim-1-rep…

A sharp and insightful talk at #KCRS25 about KIM-1 in JAVELIN Renal 101 by my dear colleague @MarcMachaalani — another key step in the evolving story of KIM-1 in RCC with more to come!! @VincentWenxinXu @DrChoueiri

👥 Connect, learn, & collaborate with your peers! Join Dr. Smith, Dr. Gao, @CaPsurvivorship, @davidjeinstein, @RickLee6 & @VincentWenxinXu at the Genitourinary Cancers State of the Science Summit on July 22! Register today: hubs.li/Q03wwJx20 @MGHCancerCenter #SOSSconnects

What an incredible slide from @VincentWenxinXu at #KCRS2025 depicting some of the individuals that have contributed to biomarker research in RCC 🔬. “Biomarkers are a lot of work, but they will reduce both overtreatment and undertreatment” @kidneycan @OncoAlert

Takeaways from @VincentWenxinXu 's majestic talk on biomarkers: - Several biomarkers have been studied in RCC - Current biomarkers in RCC do not correspond to patient's goals - The future is in integrative biomarkers - Let's get back to work to answer all the different questions…

Genitourinary Cancers State of the Science Summit is in Boston on July 22: @CaPsurvivorship and @VincentWenxinXu are both presenting on new treatment approaches and strategies in genitourinary cancers. @DanaFarber_GU

I’m still here—because KCRS connected me to a Global community that NEVER gives up. Kidney cancer doesn’t define us. Next stop: Boston July 17th & 18th-Join Us! #KCRS2025 #AcceratingCures @kidneycan @DrChoueiri @DanaFarber @DanaFarber_GU @MikeSerzanMD @BradMcG04 @VincentWenxinXu

@VincentWenxinXu on KIM-1 as a potential tool for clinical decision-making. Provocative questions on applying this to future clinical trials… #KCRS25 @kidneycan

Bright future ahead for kidney cancer with tumor neoantigen vaccine, inducing ferroptosis, KIM-1 biomarker, dual targeting CAIX/CD70 CAR-T cell. A great session at @kidneycan #KCRS25 by @EJonasch #CherylWalker @BraunMDPhD #MeiKoh #WayneMarasco @VincentWenxinXu

#KCRS25 Session 1 highlighted how federally funded research, especially through programs like the KCRP, drives real-world progress in kidney cancer treatment and patient outcomes. Building a Trial Consortium with @EJonasch Personalized Vaccines in Kidney Cancer with @BraunMDPhD…

@VincentWenxinXu hitting the stage with great data on KIM-1 Kidney injury molecule, a promising biomarker of risk recurrence and benefit prediction to ICI response. Possible future use for non invasive patient stratification for adjuvant therapy?

Can we restore NK cell anti-tumor activity against RCC? Stay tuned to follow the results of this first in human pilot study! @VincentWenxinXu #KCRS25 @OncoAlert

#KCRS25 Session 3 offered a look at cutting-edge clinical trials currently underway in kidney cancer research: Ivonescimab After Immunotherapy with @NazliDizman XmAb819 First-in-Class Study with Ritesh Kotecha Short-Term Keytruda for High-Risk RCC with @BradMcG04 177Lu-PSMA-617…

@Clara__Steiner 🧬 Plasma proteomics reveals a unique mitochondrial signature in chromophobe RCC! #KidneyCancer #PrecisionOncology @DanaFarber @BrighamWomens @DrChoueiri @LisaHenske @VincentWenxinXu @kidneycan

KIM1 is the most promising biomarker in RCC but how do we incorporate it into clinical practice? #KCRS25 @VincentWenxinXu We need to agree on what is high + randomised trials needed. It feels a distance away. Low levels may spare some adjuvant pembro but prospect testing needed.

Thank you @CJSTRAV3 @kidneycan

📢KCRS25 kicks off! 👏Truly inspired by the focus on non-clear cell renal cell carcinoma at #KCRS25. An area with important progress through clinical and translational efforts, yet still an immense need to collaborate and accelerate discovery for patients who have long been…

Let us do this ! #KCRS2025 @kidneycan @advocatekidneys @DrRanaMcKay @HHammersMD @montypal @arihakimi @tompowles1